Focal ExAblate™ MR-Guided Focused Ultrasound (MRgFUS) Treatment for Management of Organ-Confined Intermediate Risk Prostate Cancer (OC-IRPC): Evaluation of Safety and Effectiveness
This study is intended to show that ExAblate™ MRgFUS is a safe procedure that can
significantly postpone or eliminate the need of patients with organ confined intermediate
risk prostate cancer to undergo a definitive treatment (i.e., Radical Prostatectomy or
Radiation therapy) for their disease.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society